Diabetes

>

Latest News

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology
More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

November 21st 2024

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes / image credit ©Yi Zhang
Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

November 18th 2024

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research
Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit  ©Tada Images/stock.adobe.com
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

November 1st 2024

October Issue of Patient Care Online Supplement is Now Live
October Issue of Patient Care Online Supplement is Now Live

October 14th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.